Here’s your US FDA review and approval news in brief this week: BioMarin Pharmaceutical Inc.’s Voxzogo and PharmaEssentia Corporation’s Besremi stand out among the FDA’s recent approvals as the first drugs indicated for achondroplasia and polycythemia vera, respectively.
The agency also approved a new adjuvant renal cell carcinoma indication for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?